Alessandro Passardi

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 309 citations · Full text

Oncology, Medicine, Colorectal Cancer +8

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

Michele Reni, Stefano Cordio, Carlo Milandri et al. · The Lancet Oncology · 2005 · 274 citations

Pancreatic Cancer, Gastrointestinal Oncology, Medicine +8

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio et al. · The Lancet Oncology · 2022 · 246 citations · Full text

Oncology, Clinical Trials, Colorectal Cancer +9

Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs

Francesco� Fabbri, Silvia Carloni, Wainer Zoli et al. · Cancer Letters · 2013 · 214 citations

Engineering, Cancer Detection, Medicine +10

Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial

Alessandro Passardi, Oriana Nanni, Davide Tassinari et al. · Annals of Oncology · 2015 · 155 citations · Full text

Gastrointestinal Oncology, Medicine, Clinical Trials +10